Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 57

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 57
---
-current liabilities                                                    
  Deferred consideration              16       1,306           –          –  
  Borrowings                          17         118         295        463  
  Total Non-Current Liabilities                1,424         295        463  
  Current liabilities                                                        
  Trade and other payables            15       3,504       1,240      1,447  
  Deferred consideration              16         538           –          –  
  Borrowings                          17         609         169        161  
  Provisions                          18           –           –        207  
  Derivative financial liability      19         383       4,160         85  
  Total Current liabilities                    5,034       5,569      1,900  
  Total liabilities                            6,458       5,864      2,363  

  F-7  

  Table of Contents  

Biodexa Pharmaceuticals PLC

Annual Report 2024

CONSOLIDATED STATEMENTS OF FINANCIAL
POSITION(continued)

At 31 December

 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Issued capital and reserves attributable to owners of the parent                                                       
  Share capital                                                         22         11,725          6,253          1,108  
  Share premium                                                         23         93,124         86,732         83,667  
  Merger reserve                                                        23         53,003         53,003         53,003  
  Warrant reserve                                                       23            894          3,457            720  
  Accumulated deficit                                                   23      ( 150,424      ( 144,767      ( 135,336  
  Total equity                                                                      8,322          4,678          3,162  
  Total equity and liabilities                                                     14,780         10,542          5,525  

The notes form an integral part of these consolidated financial statements.

  F-8  

  Table of Contents  

Biodexa Pharmaceuticals PLC

Annual Report 2024

Consolidated statements of cash flows

For the year ended 31 December

 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Cash flows from operating activities                                                                                    
  Loss for the year                                                                    ( 5,729      ( 7,079      (